Boehringer Ingelheim RCV extend partnership with Clariness until 2028
Published by Joseph Yeomans on 18 November 2024
Berlin, Germany 18 November 2024 – Boehringer Ingelheim RCV has extended its partnership with Clariness until 2028, agreeing to list studies across all Boehringer Ingelheim RCV indications on its global patient portal, ClinLife®.
With this extension, Clariness will continue to support Boehringer Ingelheim RCV studies across Austria, Poland, and Switzerland, in local languages. Together, Clariness and Boehringer Ingelheim RCV will list and recruit patients for 30 trials per year, supporting more than 150 sites.
In listing their trials on ClinLife®, Boehringer Ingelheim RCV aims to raise patient awareness across their trial portfolio, increase the ease of patient access to participate in trials, and support sites with a one-of-a-kind, easy-to-use tool to ensure site satisfaction.
Clariness has experience in supporting recruitment of Boehringer Ingelheim RCV studies in Austria, Czech Republic, Hungary, Poland and Switzerland across many indications including systemic sclerosis, PTSD, depression, schizophrenia, oncology, hidradenitis suppurativa and more.
The long-term partnership was buoyed by the recent success of the collaboration on the CONNEX Phase III clinical trial program, from 2021-2024, aimed at improving cognition in adults with schizophrenia. Clariness was trusted to find patients from Austria and five Eastern European countries for the typically challenging recruitment of this indication. Clariness ultimately contributed 23% of enrolled patients in Poland, and 25% of enrolled patients in Austria for Connex 3.
“This extension allows us to plan for long term success, enabling the local study teams to book additional services according to their trial specific need and to work in tandem toward our shared patient recruitment targets. Our partnership so far has been marked by mutual teamwork and high-quality referrals. We look forward to seeing this continue until 2028, as we look ahead to listing even more studies on ClinLife®.” said Hermann Novak, Regional Therapeutic Area Lead CNS, Retinopathies and Emerging Areas at Boehringer Ingelheim RCV.
”We have seen through our lengthy partnership that ClinLife® works across different geographies and is a powerful solution to raise awareness of Boehringer Ingelheim RCV’s studies, allowing us to establish a trustworthy, scalable online recruitment channel.” said Csilla Ponner, Head of Clinical Operations at Boehringer Ingelheim RCV.
“This commitment is a show of belief in Clariness and the ClinLife® patient portal, reinforcing Boehringer Ingelheim RCV as a long-term strategic partner of Clariness. With ClinLife®’s patient reach continuing to grow year-on-year, having seen an 11x increase in pre-screened patient referrals since our first year of operation, we are glad Boehringer Ingelheim RCV’s patient recruitment will grow alongside us.” said Moritz Kloss, Vice President of ClinLife® Registry.
About Boehringer Ingelheim RCV
Boehringer Ingelheim RCV is a biopharmaceutical company active in both human and animal health. As one of the industry’s top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at www.boehringer-ingelheim.com.
About Clariness
Clariness provides high-end services across the clinical trial lifecycle, including study feasibility, patient recruitment, and patient retention services, for pharmaceutical companies, contract research organizations (CROs), and study sites across the globe. Dedicated to improving patients’ lives by accelerating the development of medical treatments and therapies, Clariness is the leading expert in global patient recruitment with 18+ years’ experience. Clariness has supported over 1,200 clinical trials worldwide through its market leading patient portal ClinLife®, which is active in 50+ countries, available in 35+ languages, covers 80+ indications, and welcomes 15+ million visitors per year. For more information, visit www.clariness.com and www.clinlife.com.
About ClinLife®
ClinLife® is a patient-friendly digital platform that allows users to browse indications, find matching clinical studies and apply for them via the portal. Different sponsors, sites, CROs and digital health applications list a single study or an entire portfolio of clinical trials on ClinLife®.
Press Contact: Joseph Yeomans, VP Marketing, [email protected]
